New drug combo targets brain tumor metabolism in early trial
NCT ID NCT03528642
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This early-phase trial tests a new drug (telaglenastat) added to standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The main goal is to find the safest dose and see if the combination helps shrink tumors. About 40 adults and teens aged 16 and older are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.